{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:52:43Z","timestamp":1794556363539,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jacc.2024.06.036","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T14:03:49Z","timestamp":1725890629000},"page":"1078-1088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effects of Sotagliflozin on Health Status in Patients With Worsening Heart\u00a0Failure"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6449-4535","authenticated-orcid":false,"given":"Ankeet S.","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Testani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2024.06.036_bib1","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005254","article-title":"Physical function, frailty, cognition, depression, and quality of life in hospitalized adults\u00a0\u226560 years with acute decompensated heart failure with preserved versus reduced ejection fraction","volume":"11","author":"Warraich","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.06.036_bib2","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.jacc.2019.08.001","article-title":"2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"74","author":"Hollenberg","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.036_bib3","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S1053-2498(01)00298-4","article-title":"Preferences for quality of life or survival expressed by patients with heart failure","volume":"20","author":"Lewis","year":"2001","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.jacc.2024.06.036_bib4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ejhf.2909","article-title":"Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: participant-level pooled analysis from the DAPA-HF and DELIVER trials","volume":"25","author":"Bhatt","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2024.06.036_bib5","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2024.06.036_bib6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.121.057812","article-title":"Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved Trial","volume":"145","author":"Butler","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.06.036_bib7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.06.036_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.122.059725","article-title":"Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial","volume":"146","author":"Kosiborod","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.06.036_bib9","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2024.06.036_bib10","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.06.036_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.06.036_bib12","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC State-of-the-Art Review","volume":"76","author":"Spertus","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.036_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/CIRCOUTCOMES.115.001958","article-title":"Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire","volume":"8","author":"Spertus","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2024.06.036_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.06.036_bib15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2022.11.006","article-title":"Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction","volume":"81","author":"Kosiborod","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.036_bib16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehaa1007","article-title":"Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial","volume":"42","author":"Butler","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.06.036_bib17","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.06.036_bib18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.06.036_bib19","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.036_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.39458","article-title":"New York Heart Association class and Kansas City Cardiomyopathy Questionnaire in acute heart failure","volume":"6","author":"Huo","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2024.06.036_bib21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jchf.2020.05.005","article-title":"Sacubitril\/valsartan in advanced heart failure with reduced ejection fraction: rationale and design of the LIFE trial","volume":"8","author":"Mann","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2024.06.036_bib22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart\u00a0failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.06.036_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.06.036_bib24","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.jacc.2023.08.050","article-title":"Efficacy of sotagliflozin in adults with type 2 diabetes in relation to baseline hemoglobin A1c","volume":"82","author":"Aggarwal","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.06.036_bib25","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1093\/eurheartj\/ehac417","article-title":"Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?","volume":"43","author":"Pitt","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.06.036_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.121.054442","article-title":"Does SGLT1 inhibition add benefit to SGLT2 inhibition in type 2 diabetes?","volume":"144","author":"Pitt","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.06.036_bib27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10557-021-07291-y","article-title":"The role of combined SGLT1\/SGLT2 inhibition in reducing the incidence of stroke and myocardial infarction in patients with type 2 diabetes mellitus","volume":"36","author":"Pitt","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2024.06.036_bib28","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.7326\/M21-0651","article-title":"Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure: a randomized trial","volume":"174","author":"Szarek","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2024.06.036_bib29","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jchf.2023.05.026","article-title":"Effect of sotagliflozin on early mortality and heart failure-related events: a post hoc analysis of SOLOIST-WHF","volume":"11","author":"Pitt","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2024.06.036_bib30","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jacc.2023.02.022","article-title":"Time to benefit with sotagliflozin in patients with worsening heart failure","volume":"81","author":"Verma","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724078860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724078860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T04:07:34Z","timestamp":1730347654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109724078860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0735109724078860"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.06.036","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Sotagliflozin on Health Status in Patients With Worsening Heart\u00a0Failure","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.06.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}